Numerous large studies have identified PEAR1 genetic variants as determinants of platelet response/function variability, both in the general population and in cohorts with cardiovascular outcomes [5–29], suggesting that PEAR-1 may be a signaling component, capable of modulating several functional platelet pathways in physiological conditions, but also in the context of anti-platelet therapy and cardiovascular disease. This evidence concerns the gene PEAR1 and cardiovascular disorder.